{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:41:34Z","timestamp":1791319294726,"version":"4.3.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1124\/jpet.122.001381","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T19:40:11Z","timestamp":1669059611000},"page":"277-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["HM15912, a Novel Long-Acting Glucagon-Like Peptide-2 Analog, Improves Intestinal Growth and Absorption Capacity in a Male Rat Model of Short Bowel Syndrome"],"prefix":"10.1016","volume":"384","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-8393","authenticated-orcid":false,"given":"Jaehyuk","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunjin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjoo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daejin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungmin","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001381_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.exphem.2020.09.199","article-title":"Eflapegrastim\u2019s enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing","volume":"92","author":"Barrett","year":"2020","journal-title":"Exp Hematol"},{"key":"10.1124\/jpet.122.001381_bib2","series-title":"Sleisenger and Fordtran\u2019s Gastrointestinal and Liver Disease","first-page":"1832","article-title":"Short Bowel Syndrome","author":"Buchman","year":"2016"},{"key":"10.1124\/jpet.122.001381_bib4","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1073\/pnas.93.15.7911","article-title":"Induction of intestinal epithelial proliferation by glucagon-like peptide 2","volume":"93","author":"Drucker","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001381_bib5","first-page":"139","article-title":"Structural and functional changes following small intestinal resection in the rat","volume":"32","author":"Dowling","year":"1967","journal-title":"Clin Sci"},{"key":"10.1124\/jpet.122.001381_bib6","unstructured":"EMA (2012) Revestive: EPAR - Public assessment report. EMA Website Retrieved 24\/09\/2012, from EMA https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/revestive-epar-public-assessment-report_en.pdf."},{"key":"10.1124\/jpet.122.001381_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/jpet.119.262238","article-title":"Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome","volume":"373","author":"Hargrove","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001381_bib8","first-page":"2884","article-title":"In vivo and in vitro degradation of glucagon-like peptide-2 in humans","volume":"85","author":"Hartmann","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1124\/jpet.122.001381_bib9","first-page":"S188","article-title":"A first-in-human, double-blinded, randomized, placebo-controlled, single ascending dose study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of hm15912 in healthy subjects","volume":"45","author":"Kang","year":"2021","journal-title":"J Parenter Enteral Nutr."},{"key":"10.1124\/jpet.122.001381_bib10","unstructured":"Larsen BD, Petersen YM, Ebbeh\u00f8j K (2006) Glucagon-like-peptide-2 (GLP-2) analogues. Patent No. EP2295452452; 2006."},{"key":"10.1124\/jpet.122.001381_bib11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1210\/en.2010-0822","article-title":"Mechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblasts","volume":"152","author":"Leen","year":"2011","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.122.001381_bib12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0016-5085(99)70388-4","article-title":"Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome","volume":"117","author":"Messing","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.122.001381_bib13","first-page":"233","article-title":"Resection of the small intestine in rats. 3. Morphological changes in the intestinal tract","volume":"133","author":"Nygaard","year":"1967","journal-title":"Acta Chir Scand"},{"key":"10.1124\/jpet.122.001381_bib14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cgh.2005.10.002","article-title":"Short bowel syndrome and intestinal failure: consensus definitions and overview","volume":"4","author":"O\u2019Keefe","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/jpet.122.001381_bib15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clnu.2016.01.020","article-title":"ESPEN guidelines on chronic intestinal failure in adults","volume":"35","author":"Pironi","year":"2016","journal-title":"Clin Nutr"},{"key":"10.1124\/jpet.122.001381_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/17474124.2018.1417032","article-title":"Glucagon like peptide-2 and neoplasia; a systematic review","volume":"12","author":"Ring","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1124\/jpet.122.001381_bib17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/jpet.122.001381_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.mce.2008.02.014","article-title":"Life in the crypt: a role for glucagon-like peptide-2?","volume":"288","author":"Rowland","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1124\/jpet.122.001381_bib19","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1152\/ajpgi.00039.2011","article-title":"The \u201ccryptic\u201d mechanism of action of glucagon-like peptide-2","volume":"301","author":"Rowland","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1124\/jpet.122.001381_bib20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/01.sla.0000179647.24046.03","article-title":"Pediatric short bowel syndrome: redefining predictors of success","volume":"242","author":"Spencer","year":"2005","journal-title":"Ann Surg"},{"key":"10.1124\/jpet.122.001381_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1026697915937","article-title":"Factors affecting outcome following proximal and distal intestinal resection in the dog: an examination of the relative roles of mucosal adaptation, motility, luminal factors, and enteric peptides","volume":"44","author":"Thompson","year":"1999","journal-title":"Dig Dis Sci"},{"key":"10.1124\/jpet.122.001381_bib22","unstructured":"U.S. FDA (2003) Zorbtive (somatropin [rDNA origin] for injection). Full prescribing information. FDA Website Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020604s090lbl.pdf."},{"key":"10.1124\/jpet.122.001381_bib23","unstructured":"U.S. FDA (2012) GATTEX (teduglutide [rDNA origin]), for injection, for subcutaneous use. Initial U.S. Approval: 2012 FDA Website Retrieved from U.S. FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203441Orig1s000lbl.pdf."},{"key":"10.1124\/jpet.122.001381_bib24","unstructured":"U.S. FDA (2014) GATTEX (teduglutide [rDNA origin]) Injection drug approval package - summary review (NDA 203441\/S-002). FDA Website Retrieved 26\/06\/2014 from U.S. FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/203441Orig1s002.pdf."},{"key":"10.1124\/jpet.122.001381_bib25","unstructured":"U.S. NIDDK (2015) Short Bowel Syndrome. Website Retrieved from U.S. FDA https:\/\/www.niddk.nih.gov\/health-information\/digestive-diseases\/short-bowel-syndrome."},{"key":"10.1124\/jpet.122.001381_bib26","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s002680010266","article-title":"Short bowel syndrome","volume":"24","author":"Wilmore","year":"2000","journal-title":"World J Surg"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524003963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524003963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:17:57Z","timestamp":1739971077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524003963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0022356524003963"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001381","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HM15912, a Novel Long-Acting Glucagon-Like Peptide-2 Analog, Improves Intestinal Growth and Absorption Capacity in a Male Rat Model of Short Bowel Syndrome","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}